Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC) - Concepedia

Concepedia

Publication | Closed Access

Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC)

69

Citations

9

References

2007

Year

Charles J. Ryan, Walter M. Stadler, Bruce J. Roth, Douglass Hutcheon, Shauna Conry, Thomas A. Puchalski, Charles Morris, Eric J. Small

Investigational New Drugs

UrologyGenitourinary CancerMedicinePharmacologyPharmacokinetic StudyPharmacotherapyProstatic DiseaseOncology

References

	Year	Citations

Page 1